Results 11 to 20 of about 586,353 (306)

Perceptions and patient care needs among hepatitis B patients during COVID-19

BMC Health Services Research, 2022
Background The novel coronavirus of 2019 (COVID-19) has been and continues to be a rapidly developing public health crisis, that has also disrupted routine and maintenance health care for people living with chronic conditions.
Sherrie Flynt Wallington, Min Jeong Jeon, T. Angeline Nguyen, Choosonjargal Byambaa, Y. Tony Yang, Daisy Le   +5 more
doaj   +1 more source

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B

Vaccines, 2022
Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Julio Cesar Aguilar, Jorge Agustin Aguiar, Sheikh Mohammad Fazle Akbar   +2 more
doaj   +1 more source

Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas^® HBV Test for Use on the Cobas^® 4800 System

Microorganisms, 2021
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection.
Valérie Ortonne, Mélanie Wlassow, Magali Bouvier-Alias, Giovana Melica, Jean-Dominique Poveda, Syria Laperche, Jean-Michel Pawlotsky, Stephane Chevaliez   +7 more
doaj   +1 more source

Autophagy by hepatitis B virus and for hepatitis B virus [PDF]

Autophagy, 2010
Autophagy is a catabolic process by which cells remove unwanted proteins and damaged organelles. It is important for maintaining cellular homeostasis and can also be used by cells to remove intracellular microbial pathogens. As such, some viruses such as herpes simplex virus-1 (HSV-1) have evolved mechanisms to suppress autophagy for their survival. In
Donna, Sir, David K, Ann, Jing-Hsiung James, Ou   +2 more
openaire   +2 more sources

Boosting Diverse Communities Participation in Clinical Trials: What People Living with Hepatitis B Must Know [PDF]

BioSocial Health Journal
Introduction: Globally, people from African, Asian and Western Pacific regions are disproportionately affected by hepatitis B virus (HBV) and are underrepresented in HBV clinical trials (trials).
Yasmin Ibrahim, Tanya Machado, Fiona Borondy-Jenkins, Shreya Koirala, Mi Dong, Ibrahima Sankare, Mohamed Ali, Dung Hua, Ashley Che, Chari Cohen   +9 more
doaj   +1 more source

Management of acute hepatitis B and reactivation of hepatitis B [PDF]

Liver International, 2013
AbstractThe natural course of hepatitis B virus infection and the resulting hepatic injury is determined by the degree of virus replication and the intensity of host immune response. Upon exposure to hepatitis B virus (HBV), individuals with a vigorous and broad immune response develop acute self‐limited infection, which may result in acute hepatitis ...
Ankur, Jindal, Manoj, Kumar, Shiv K, Sarin   +2 more
openaire   +2 more sources

IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection

Viruses, 2022
The Na+/taurocholate co-transporting polypeptide (NTCP, gene symbol SLC10A1) is both a physiological bile acid transporter and the high-affinity hepatic receptor for the hepatitis B and D viruses (HBV/HDV).
Massimo Palatini, Simon Franz Müller, Michael Kirstgen, Silke Leiting, Felix Lehmann, Lena Soppa, Nora Goldmann, Christin Müller, Kira Alessandra Alicia Theresa Lowjaga, Jörg Alber, Giuliano Ciarimboli, John Ziebuhr, Dieter Glebe, Joachim Geyer   +13 more
doaj   +1 more source

Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac

Vaccines, 2021
Background and aims: Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn.
Rifaat Safadi, Tawfik Khoury, Nizar Saed, Marwan Hakim, Jeryes Jamalia, Yousef Nijim, Nicola Farah, Tawfik Nuser, Nidaa Natur, Mahmud Mahamid, Johnny Amer, Pia L. Roppert, Wolfram H. Gerlich, Dieter Glebe   +13 more
doaj   +1 more source

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors

Viruses, 2021
Identification of Na+/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV
Michael Kirstgen, Kira Alessandra Alicia Theresa Lowjaga, Simon Franz Müller, Nora Goldmann, Felix Lehmann, Dieter Glebe, Karl-Heinz Baringhaus, Joachim Geyer   +7 more
doaj   +1 more source

Epidemiology of hepatitis B [PDF]

The Pediatric Infectious Disease Journal, 1993
An estimated 200,000 to 300,000 hepatitis B virus infections occur annually in the United States. With acute infection, symptoms develop in fewer than 5% of infants, 5 to 15% of children between the ages of 1 and 5 years and 33 to 50% of older children and adults. However, the risk of chronic infection after acute infection is inversely proportional to
openaire   +3 more sources